HighTower Advisors
ADAP

HighTower Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

HighTower Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,150
Closed -$31K – 3225
2022
Q1 		$31K Buy
15,150
+1,150
+8% +$3.1K ﹤0.01% 3120
2021
Q4 		$53K Hold
14,000
– – ﹤0.01% 3016
2021
Q3 		$72K Sell
14,000
-1,000
-7% -$4.49K ﹤0.01% 2894
2021
Q2 		$64K Buy
+15,000
New +$72.8K ﹤0.01% 2865

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighTower Advisors's ADAP Position: Q2 2022 in Review

HighTower Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q2 2022, closing a stake of 15,150 shares — an estimated $31K sold.

HighTower Advisors first reported a position in ADAP in Q2 2021 and held it in 4 quarters. The position peaked at $72K in Q3 2021. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2022.

  • HighTower Advisors reported no remaining Adaptimmune Therapeutics position as of Q2 2022 after selling out during the quarter.
  • HighTower Advisors sold 15,150 Adaptimmune Therapeutics shares in Q2 2022, an estimated $31K.
  • HighTower Advisors first reported a position in Adaptimmune Therapeutics in Q2 2021 and held it in 4 quarters.
  • HighTower Advisors's Adaptimmune Therapeutics position peaked at $72K in Q3 2021.
  • 77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2022.

Based on HighTower Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.